Sandra Calvin, SVP, Chief Accounting Officer: Travere Therapeutics TVTX Sell · Filed 25/12/29

Trade details

Type: Insider sale
Amount: $296,080
Shares · price: 7,402 sh · $40.00 a share
Held after: 38,233 sh
Stock: Travere Therapeutics TVTX
Person: Sandra CalvinSVP, Chief Accounting Officer
Trade date: 25/12/24
Filed: 25/12/29
Days to filing: 5 days

Sold 16.2% of holdings

Share of holding sold: 16.2%

Travere Therapeutics trades, last 26 weeks

What else happened in Travere Therapeutics around then

Filed or reported within 30 days of the trade day · 25/11/24~01/23

Sandra Calvin's recent trades

Sandra CalvinSVP, Chief Accounting Officer
Planned sale10b5-1 planTravere Therapeutics
Planned sale10b5-1 plan
Travere Therapeutics
TVTX
$353.6K
5,375 sh
$353.6K
Filed 09/15
Traded 09/15
Sandra CalvinSVP, Chief Accounting Officer
Sell10b5-1 planTravere Therapeutics
Sell10b5-1 plan
Travere Therapeutics
TVTX
$902.6K
21,977 sh
$902.6K
Filed 04/16
Traded 04/14
Sandra CalvinSVP, Chief Accounting Officer
Planned sale10b5-1 planTravere Therapeutics
Planned sale10b5-1 plan
Travere Therapeutics
TVTX
$902.6K
21,977 sh
$902.6K
Filed 04/14
Traded 04/14
Sandra CalvinSVP, Chief Accounting Officer
Planned saleTravere Therapeutics
Planned sale
Travere Therapeutics
TVTX
$139.2K
4,333 sh
$139.2K
Filed 02/03
Traded 02/03
Sandra CalvinSVP, Chief Accounting Officer
SellTravere Therapeutics
Sell
Travere Therapeutics
TVTX
$139.2K
4,333 sh
$139.2K
Filed 02/03
Traded 02/03